Drug Profile


Alternative Names: Semoxind; SU 5416

Latest Information Update: 20 Jun 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cancer metastases; Colorectal cancer; Kaposi's sarcoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 08 Feb 2002 Discontinued - Phase-I for Cancer metastases in USA (IV)
  • 08 Feb 2002 Discontinued - Phase-I for Solid tumours in Switzerland (PO)
  • 08 Feb 2002 Discontinued - Phase-I for Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top